Back to search results

Colchicine for Uremic Cardiomyopathy in Chronic Kidney Disease

This study is testing whether colchicine, a medication, can help people with chronic kidney disease (CKD) who also have uremic cardiomyopathy (heart problems related to kidney disease). Researchers want to see if colchicine is safe and effective. You might be able to join if you are between 21 and 80 years old, have an eGFR (a measure of kidney function) between 15 and 75 mL/min, and a urine albumin-to-creatinine ratio greater than 30 mg/g. The study will compare colchicine to a placebo (an inactive substance) to see if colchicine can improve a measure of heart function called left ventricular global longitudinal strain after 4 weeks. The current status of this study is unclear, and it plans to enroll 20 participants.

Study design
This is an interventional study comparing colchicine to a placebo. It plans to enroll 20 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 4 weeks, which suggests a follow-up period of at least 4 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04500665

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

Recruiting
PHASE2Ages 21–80InterventionalTreatment
Brigham and Women's Hospital
~20 participants
Updated 2025-09-23 on ClinicalTrials.gov
What's tested:ColchicinePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Between-group change in left ventricular global longitudinal strain
Measured over 4 weeks

Conditions

Chronic Kidney Diseases

Explore related trials

Chronic Kidney Disease

NCT04500665

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brigham and Women's Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Leo F Buckley, PharmD MPH · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital

Who to contact

Leo F Buckley, PharmD MPH
[email protected]
617-732-5500
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 21 years to 80 years (inclusive)
eGFR of 15 to 75 mL/min per 1.73 m2
Urine albumin-to-creatinine ratio of greater than 30 mg/g
Use of maximally tolerated doses of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker if urine albumin-to-creatinine ratio greater than 300 mg-g
Use of a sodium-glucose co-transporter-2 inhibitor if indicated in the opinion of the participant's primary clinician
Willing and able to provide written informed consent and to adhere to the study protocol

What this trial measures

  • Between-group change in left ventricular global longitudinal strain4 weeks

    Assessed using transthoracic echocardiography